|
Change of Director's Interest Notice
|
30 June 2023 at 2:20pm
|
|
Change of Registered Office
|
26 June 2023 at 4:20pm
|
|
IHL Announcement - H.C. Wainwright Virtual Conference
|
23 June 2023 at 8:40am
|
|
Principal Investigators Appointed for IHL42X Phase 2/3 Trial
|
16 June 2023 at 8:40am
|
|
Change of Director's Interest Notice
|
6 June 2023 at 4:15pm
|
|
Notification regarding unquoted securities - IHL
|
2 June 2023 at 11:10am
|
|
International Psychedelics Experts Join Clarion Clinics
|
30 May 2023 at 9:00am
|
|
Entitlement Offer of Loyalty Options Oversubscribed
|
30 May 2023 at 8:40am
|
|
Psychennex Pty Ltd - Company Update
|
16 May 2023 at 9:10am
|
|
Lease Secured for Psychedelic Clinic
|
5 May 2023 at 9:10am
|
|
IHL-675A Phase 1 Results Presentation
|
3 May 2023 at 9:55am
|
|
Non-Renounceable Issue
|
3 May 2023 at 9:50am
|
|
Incannex Announces Final Results from Phase 1 Clinical Trial
|
2 May 2023 at 8:40am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
27 April 2023 at 8:40am
|
|
Proposed issue of securities - IHL
|
26 April 2023 at 8:40am
|
|
Cancel - Proposed issue of securities - IHL
|
24 April 2023 at 1:45pm
|
|
Proposed issue of securities - IHL
|
21 April 2023 at 9:35am
|
|
Entitlement Offer of Loyalty Options
|
21 April 2023 at 8:40am
|
|
Global CRO leader QPS engaged for CannQuit & ReneCann
|
14 April 2023 at 8:40am
|
|
Incannex Launches Psychedelic Clinics Business
|
16 March 2023 at 10:25am
|
|
Reinstatement to Official Quotation
|
15 March 2023 at 10:25am
|
|
Interim phase 2 PsiGAD psilocybin results
|
15 March 2023 at 10:25am
|
|
Voluntary Suspension
|
14 March 2023 at 10:30am
|
|
Trading Halt
|
10 March 2023 at 10:35am
|
|
Pause in Trading
|
10 March 2023 at 10:10am
|
|
Incannex to Manufacture Psilocybin for Trials & Commercial
|
3 March 2023 at 8:40am
|
|
IHL Commences Phase 2 Clinical Trial
|
28 February 2023 at 9:40am
|
|
Appendix 4D and Half Year Accounts
|
27 February 2023 at 12:10pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
27 January 2023 at 8:55am
|
|
Independent data review commences for Ph 2 trial psilocybin
|
18 January 2023 at 8:50am
|
|
Appendix 3Y R Clark
|
28 December 2022 at 8:40am
|
|
Notification regarding unquoted securities - IHL
|
16 December 2022 at 11:55am
|
|
Proposed issue of securities - IHL
|
15 December 2022 at 5:40pm
|
|
Cleansing Statement
|
9 December 2022 at 4:25pm
|
|
Notification regarding unquoted securities - IHL
|
9 December 2022 at 4:25pm
|
|
Application for quotation of securities - IHL
|
9 December 2022 at 4:20pm
|
|
Incannex Expands Intellectual Property Position over IHL-42X
|
6 December 2022 at 8:50am
|
|
Prospectus for Placement Options
|
5 December 2022 at 5:35pm
|
|
Proposed issue of securities - IHL
|
5 December 2022 at 5:10pm
|
|
Capital Raising Presentation
|
5 December 2022 at 10:15am
|
|
Incannex Undertakes A$13 Million Institutional Placement
|
5 December 2022 at 9:55am
|
|
Trading Halt
|
1 December 2022 at 8:55am
|
|
Results of Meeting
|
29 November 2022 at 6:45pm
|
|
IHL Annual General Meeting CEO Address
|
29 November 2022 at 5:05pm
|
|
IHL commences manufacturing of skin therapeutics
|
29 November 2022 at 8:45am
|
|
IHL Commences Manufacturing for Novel Addiction Treatments
|
25 November 2022 at 8:45am
|
|
Addendum to Notice of Annual General Meeting
|
21 November 2022 at 8:40am
|
|
Incannex Development Update for IHL-42X
|
17 November 2022 at 8:45am
|
|
Incannex files Form 20-F and XBRL Data with SEC
|
31 October 2022 at 10:05am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 October 2022 at 8:30am
|
Incannex Healthcare